[Use of LDBIO Diagnostics ® TOXOPLASMA ICT IGG-IGM in association with Siemens Atellica ® IM in toxoplasmosis serological screening].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Fortun M; L'hirondel J
  • Source:
    Annales de biologie clinique [Ann Biol Clin (Paris)] 2024 Apr 19; Vol. 82 (1), pp. 81-92.
  • Publication Type:
    English Abstract; Journal Article
  • Language:
    French
  • Additional Information
    • Transliterated Title:
      Place du test rapide LDBIO Diagnostics® TOXOPLASMA ICT IGG-IGM en complément de la sérologie Siemens Atellica® IM dans la stratégie diagnostique de la toxoplasmose.
    • Source:
      Publisher: John Libbey Eurotext Country of Publication: France NLM ID: 2984690R Publication Model: Print Cited Medium: Internet ISSN: 1950-6112 (Electronic) Linking ISSN: 00033898 NLM ISO Abbreviation: Ann Biol Clin (Paris) Subsets: MEDLINE
    • Publication Information:
      Publication: Montrouge : John Libbey Eurotext
      Original Publication: Paris : Expansion scientifique française.
    • Subject Terms:
      Toxoplasma* ; Toxoplasmosis*/diagnosis; Humans ; Immunoglobulin G ; Antibodies, Protozoan ; Immunoglobulin M
    • Abstract:
      According to French recommendations for serological screening of toxoplasmosis, some profiles must be confirmed by additional methods, extending the time taken to produce results. Thus, the Laborizon Bretagne technical platform in Nantes studied the place of the LDBIO Diagnostics® TOXOPLASMA ICT IGG-IGM (ICT) test in addition to Siemens Atellica® serology. IgG-/IgM+ and equivocal or weak positive IgG/IgM- (IgGEq/IgM-) profiles on Atellica® will be confirmed by ICT, Alinity® Abbott and Platelia® Biorad. Among the 66 IgGEq/IgM- profiles, the concordance is perfect between ICT and complementary techniques: 21 weak positives were confirmed positive, 8 equivocal were considered negative and 37 were confirmed positive. Concerning the 76 IgG-/IgM+ profiles, 68 are negative and 7 are positive by complementary techniques and ICT. One discordance was observed. The Atellica®/ICT combination allows excellent discrimination of IgG-/IgM+ and IgGEq/IgM serological profiles with consistent diagnostic orientation in 99.3% of cases. Only 1 sample was found to be discordant but required monitoring at 15 days. The observed performances are compatible with routine use. This test simplifies the analytical process, improves the time to obtain results, while guaranteeing an excellent level of quality.
    • Contributed Indexing:
      Keywords: clinical biology; confirmation testing; immunology; microbiology; performances; serology
    • Accession Number:
      0 (Immunoglobulin G)
      0 (Antibodies, Protozoan)
      0 (Immunoglobulin M)
    • Publication Date:
      Date Created: 20240419 Date Completed: 20240422 Latest Revision: 20240422
    • Publication Date:
      20240422
    • Accession Number:
      10.1684/abc.2024.1875
    • Accession Number:
      38638021